Chicago Partners Investment Group LLC Has $575,000 Stock Holdings in Edwards Lifesciences Corporation $EW

Chicago Partners Investment Group LLC increased its position in Edwards Lifesciences Corporation (NYSE:EW) by 12.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,479 shares of the medical research company’s stock after buying an additional 854 shares during the period. Chicago Partners Investment Group LLC’s holdings in Edwards Lifesciences were worth $575,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in EW. Nuveen LLC acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $330,881,000. Jennison Associates LLC grew its stake in shares of Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after buying an additional 2,576,383 shares during the period. Mirova US LLC grew its stake in shares of Edwards Lifesciences by 56.2% in the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after buying an additional 1,054,301 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $67,832,000. Finally, Woodline Partners LP grew its stake in shares of Edwards Lifesciences by 7,805.0% in the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock valued at $59,822,000 after buying an additional 814,917 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $76.03 on Wednesday. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.00. The company’s 50 day moving average price is $77.46 and its two-hundred day moving average price is $76.25. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock has a market cap of $44.64 billion, a P/E ratio of 10.94, a P/E/G ratio of 3.61 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter last year, the firm earned $0.70 EPS. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on EW. JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Morgan Stanley raised their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research report on Friday, July 25th. Finally, Argus raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Thursday, July 10th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $87.06.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.